Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont in pediatric congenital adrenal hyperplasia
NCT04806451Phase 3Active, not recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of crinecerfont in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Started Jun 2021; status: active, not recruiting.
02
Drugs
crinecerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT04806451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806451.